Navigation Links
Bioniche Pharma Launches Enlon(R) and Enlon-Plus(R) Injection
Date:5/14/2009

LAKE FOREST, Ill., May 14 /PRNewswire/ -- - Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced the launch of Enlon(R) (edrophonium chloride injection, USP) and Enlon-Plus(R) (edrophonium chloride, USP and atropine sulfate, USP) Injection.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

"The acquisition and launch of Enlon(R) represent Bioniche's continued growth and a commitment to bringing this important therapy back to market and into the hands of health care professionals," said Steve Thornton, CEO, Bioniche Pharma.

Bioniche purchased the rights and certain assets related to the Enlon(R) product line from Baxter Corporation, which discontinued Enlon(R) in February 2008. According to IMS data, 2007 sales of Enlon(R) and Enlon-Plus(R) totaled $2,727,000 and 307,000 units.

Bioniche will supply Enlon(R) in 10 mg/mL, 15 mL vials and Enlon-Plus(R) in 15 mL vials, in addition to the currently available 5 mL ampul of Enlon-Plus(R).

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology and dermatology. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at www.bionichepharma.com.


'/>"/>
SOURCE Bioniche Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Bioniche Reports Fiscal 2007 Year-End Results
2. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... The report "Direct-Fed Microbials Market by Type (Lactic Acid Bacteria and Bacillus), Livestock (Pork/Swine, ... Forecast to 2022", published by MarketsandMarkets, the global market is estimated to be ... Million by 2022, at a CAGR of 6.96% from 2016. ... ... Logo ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... society for optics and photonics , are commending the U.S. Congress and President ... signing Friday by the President of the American Innovation and Competitiveness Act (AICA). ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... cellular response analysis platform to measure the proteomic function of individual cells in ... Innovation Research (SBIR) grant from the National Institute on Aging of the National ...
(Date:1/11/2017)... England , PITTSBURGH and BENGALURU, ... -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE ... Food and Drug Administration (FDA) has accepted Mylan,s biologics ... for filing through the 351(k) pathway. This product is ... to treat certain HER2-positive breast cancers. The anticipated FDA ...
Breaking Biology Technology:
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... -- BioCatch , the global leader in behavioral biometrics, ... grew to over 40 granted and pending patents. ... , , The Company,s IP ... System, Device, and Method Estimating Force Applied to a Touch Surface, ... costly hardware components needed to estimate the force and pressure applied to ...
(Date:12/6/2016)... -- Valencell , the leading innovator in performance ... third consecutive year of triple digit growth for its ... a 360 percent increase in companies who have acquired ... by sales of its wrist and ear Benchmark™ sensor ... for hearables for fitness and healthcare applications. ...
Breaking Biology News(10 mins):